Provided by Tiger Trade Technology Pte. Ltd.

Ashland

59.77
+1.121.91%
Post-market: 59.770.00000.00%17:49 EST
Volume:1.52M
Turnover:90.00M
Market Cap:2.74B
PE:-3.25
High:60.27
Open:58.16
Low:57.85
Close:58.65
52wk High:74.57
52wk Low:45.21
Shares:45.76M
Float Shares:41.77M
Volume Ratio:1.30
T/O Rate:3.63%
Dividend:1.64
Dividend Rate:2.74%
EPS(TTM):-18.3696
EPS(LYR):-18.3696
ROE:-34.45%
ROA:2.05%
PB:1.44
PE(LYR):-3.25

Loading ...

Oncopeptides’ NK Cell Engager Study to be Presented at ASH

TIPRANKS
·
Nov 03

BioInvent to Present Promising Phase 2a Data at ASH 2025

TIPRANKS
·
Nov 03

Autolus Therapeutics to present data at ASH Meeting

TIPRANKS
·
Nov 03

Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025

TIPRANKS
·
Nov 03

Cellectis to present development update for eti-cel at ASH 2025

TIPRANKS
·
Nov 03

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

GlobeNewswire
·
Nov 03

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

GlobeNewswire
·
Nov 03

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

GlobeNewswire
·
Nov 03

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

GlobeNewswire
·
Nov 03

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

GlobeNewswire
·
Nov 03

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

GlobeNewswire
·
Nov 03

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

GlobeNewswire
·
Nov 03

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
Nov 03

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

GlobeNewswire
·
Nov 03

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

GlobeNewswire
·
Nov 03

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 03

Press Release: Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Dow Jones
·
Nov 03

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

GlobeNewswire
·
Nov 03

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

GlobeNewswire
·
Nov 03

Galecto to Highlight GB3226 Program at ASH 2025

GlobeNewswire
·
Nov 03